The authors screened out ERα-specific targeted inhibitors by compounds and found almost all of them ineffective in the analysis of 150 additional proteins, but there may still be some non-targeted effects that require further improvements to the chemicals to further clinically develop FEN1-targeted therapies for breast cancer. This evidence concerns the gene ESR1 and breast carcinoma.